Drugs / IMC-I109V
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05867056 | Aug 2020 → Sep 2024 | chronic hepatitis B virus infection | Immunocore Ltd | Withdrawn | No outcome recorded Stop: Enrollment |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-11-07 | Immunocore Ltd | Results Immunocore presents Phase 1 data for hepatitis B candidate at AASLD’s The Liver Meeting immunocore.com ↗
Single ascending dose data show IMC-I109V has manageable safety profile and antiviral activity |
| 2022-06-25 | Immunocore Ltd | Results Immunocore announces the presentation of initial data from the Phase 1 ImmTAV® trial for chronic Hepatitis B at the EASL International Liver Congress™ immunocore.com ↗
In the initial cohort, HBsAg declines and ALT elevations indicated that a single, very low dose of IMC-I109V elicited on-target activity, consistent with mechanism of action and without any adverse events |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-11-07 | Immunocore Ltd | Immunocore presents Phase 1 data for hepatitis B candidate at AASLD’s The Liver Meeting immunocore.com ↗ |
| 2022-06-25 | Immunocore Ltd | Immunocore announces the presentation of initial data from the Phase 1 ImmTAV® trial for chronic Hepatitis B at the EASL International Liver Congress™ immunocore.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMC-I109V | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05867056 ↗ |
| Modality | Protein / enzyme biologic | “IMC-I109V is an immune-mobilizing monoclonal T cell receptor (TCR) against viruses (ImmTAV®), a new class of bispecific protein therapeutics designed for the treatment of...” NCT05867056 ↗ |